Table 3 Pharmacokinetic parameters following a 150 mg/kg taurolidine infusion over 2 hrs
From: Pharmacokinetic study and evaluation of the safety of taurolidine for dogs with osteosarcoma
ID | Cmax (ug/mL) | Tmax (hr) | Lambda_z (1/hr) | t1/2 (hr) | AUClast (hr*ug/mL) | AUCINF (hr*ug/mL) | CL (L/hr/kg) | Vss (L/kg) | MRT (hr) |
|---|---|---|---|---|---|---|---|---|---|
1 | 65.6 | 1.50 | 0.192 | 3.6 | 178 | 197 | 0.763 | 3.11 | 4.1 |
2 | 144.8 | 2.00 | 0.203 | 3.4 | 667 | 680 | 0.221 | 0.85 | 3.9 |
3 | 185.0 | 1.50 | 0.201 | 3.5 | 457 | 467 | 0.321 | 0.97 | 3.0 |
4 | 145.1 | 1.25 | 0.201 | 3.4 | 337 | 339 | 0.442 | 1.26 | 2.8 |
5 | 162.5 | 2.08 | 0.183 | 3.8 | 684 | 698 | 0.215 | 1.09 | 5.1 |
6 | 139.7 | 1.75 | 0.272 | 2.6 | 346 | 348 | 0.431 | 1.09 | 2.5 |
Mean | 140.5 | 1.63* | 0.209 | 3.4 | 445 | 455 | 0.399 | 1.39 | 3.6 |
SD | 40.3 | NA | 0.032 | 0.4 | 200 | 201 | 0.204 | 0.85 | 0.9 |
CV% | 28.7 | NA | 15.3 | 12.7 | 44.9 | 44.1 | 51.0 | 60.9 | 26.5 |